1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Longitudinal DNA methylation analysis of adult-type IDH-mutant gliomas

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Diffuse gliomas are the most prevalent malignant primary brain tumors in adults and remain incurable despite standard therapy. Tumor recurrence is currently inevitable, which contributes to a persistent high morbidity and mortality in these patients. In this study, we examined the genome-wide DNA methylation profiles of primary and recurrent adult-type IDH-mutant gliomas to elucidate DNA methylation changes associated with tumor progression (with or without malignant transformation). We analyzed DNA methylation profiles of 37 primary IDH-mutant gliomas and 42 paired recurrences using the DNA methylation EPIC beadChip array. DNA methylation-based classification reflected the tumor progression over time. We observed a methylation subtype switch in a proportion of IDH-mutant astrocytomas; the primary tumors were subclassified as low-grade astrocytomas, which progressed to high-grade astrocytomas in the recurrent tumors. The CNS WHO grade 4 IDH-mutant astrocytomas did not always resemble methylation subclasses of higher grades. The number of differentially methylated CpG sites increased over time, and astrocytomas accumulated more differentially methylated CpG sites than oligodendrogliomas during tumor progression. Few differentially methylated CpG sites were shared between patients. We demonstrated that DNA methylation profiles are mostly maintained during IDH-mutant glioma progression, but CpG site-specific methylation alterations can occur.

          Supplementary Information

          The online version contains supplementary material available at 10.1186/s40478-023-01520-1.

          Related collections

          Most cited references35

          • Record: found
          • Abstract: found
          • Article: found

          The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

          The 2016 World Health Organization Classification of Tumors of the Central Nervous System is both a conceptual and practical advance over its 2007 predecessor. For the first time, the WHO classification of CNS tumors uses molecular parameters in addition to histology to define many tumor entities, thus formulating a concept for how CNS tumor diagnoses should be structured in the molecular era. As such, the 2016 CNS WHO presents major restructuring of the diffuse gliomas, medulloblastomas and other embryonal tumors, and incorporates new entities that are defined by both histology and molecular features, including glioblastoma, IDH-wildtype and glioblastoma, IDH-mutant; diffuse midline glioma, H3 K27M-mutant; RELA fusion-positive ependymoma; medulloblastoma, WNT-activated and medulloblastoma, SHH-activated; and embryonal tumour with multilayered rosettes, C19MC-altered. The 2016 edition has added newly recognized neoplasms, and has deleted some entities, variants and patterns that no longer have diagnostic and/or biological relevance. Other notable changes include the addition of brain invasion as a criterion for atypical meningioma and the introduction of a soft tissue-type grading system for the now combined entity of solitary fibrous tumor / hemangiopericytoma-a departure from the manner by which other CNS tumors are graded. Overall, it is hoped that the 2016 CNS WHO will facilitate clinical, experimental and epidemiological studies that will lead to improvements in the lives of patients with brain tumors.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

            The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the classification of brain and spinal cord tumors. Building on the 2016 updated fourth edition and the work of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy, the 2021 fifth edition introduces major changes that advance the role of molecular diagnostics in CNS tumor classification. At the same time, it remains wedded to other established approaches to tumor diagnosis such as histology and immunohistochemistry. In doing so, the fifth edition establishes some different approaches to both CNS tumor nomenclature and grading and it emphasizes the importance of integrated diagnoses and layered reports. New tumor types and subtypes are introduced, some based on novel diagnostic technologies such as DNA methylome profiling. The present review summarizes the major general changes in the 2021 fifth edition classification and the specific changes in each taxonomic category. It is hoped that this summary provides an overview to facilitate more in-depth exploration of the entire fifth edition of the WHO Classification of Tumors of the Central Nervous System.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data

              The Cancer Genome Atlas (TCGA) research network has made public a large collection of clinical and molecular phenotypes of more than 10 000 tumor patients across 33 different tumor types. Using this cohort, TCGA has published over 20 marker papers detailing the genomic and epigenomic alterations associated with these tumor types. Although many important discoveries have been made by TCGA's research network, opportunities still exist to implement novel methods, thereby elucidating new biological pathways and diagnostic markers. However, mining the TCGA data presents several bioinformatics challenges, such as data retrieval and integration with clinical data and other molecular data types (e.g. RNA and DNA methylation). We developed an R/Bioconductor package called TCGAbiolinks to address these challenges and offer bioinformatics solutions by using a guided workflow to allow users to query, download and perform integrative analyses of TCGA data. We combined methods from computer science and statistics into the pipeline and incorporated methodologies developed in previous TCGA marker studies and in our own group. Using four different TCGA tumor types (Kidney, Brain, Breast and Colon) as examples, we provide case studies to illustrate examples of reproducibility, integrative analysis and utilization of different Bioconductor packages to advance and accelerate novel discoveries.
                Bookmark

                Author and article information

                Contributors
                sandra.ferreyra.vega@gu.se
                thomas.olsson@vgregion.se
                teresia.kling@gu.se
                jakola.asgeir@gu.se
                helena.caren@gu.se
                Journal
                Acta Neuropathol Commun
                Acta Neuropathol Commun
                Acta Neuropathologica Communications
                BioMed Central (London )
                2051-5960
                4 February 2023
                4 February 2023
                2023
                : 11
                : 23
                Affiliations
                [1 ]GRID grid.8761.8, ISNI 0000 0000 9919 9582, Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, , University of Gothenburg, ; Blå Stråket 7, 413 45 Gothenburg, Sweden
                [2 ]GRID grid.8761.8, ISNI 0000 0000 9919 9582, Sahlgrenska Center for Cancer Research, Department of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, , University of Gothenburg, ; Gothenburg, Sweden
                [3 ]GRID grid.8761.8, ISNI 0000 0000 9919 9582, Department of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, , University of Gothenburg, ; Gothenburg, Sweden
                [4 ]GRID grid.1649.a, ISNI 000000009445082X, Department of Clinical Pathology, , Sahlgrenska University Hospital, ; Gothenburg, Sweden
                [5 ]GRID grid.1649.a, ISNI 000000009445082X, Department of Neurosurgery, , Sahlgrenska University Hospital, ; Gothenburg, Sweden
                [6 ]GRID grid.52522.32, ISNI 0000 0004 0627 3560, Department of Neurosurgery, , St. Olavs University Hospital, ; Trondheim, Norway
                Author information
                http://orcid.org/0000-0002-8584-555X
                Article
                1520
                10.1186/s40478-023-01520-1
                9899392
                36739454
                4aef284d-af9b-4e24-bb84-785fe89c2972
                © The Author(s) 2023

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 14 December 2022
                : 24 January 2023
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100002794, Cancerfonden;
                Funded by: FundRef http://dx.doi.org/10.13039/501100001858, VINNOVA;
                Funded by: Swedish state under the agreement between the Swedish government and the county councils - the ALF-agreement
                Funded by: FundRef http://dx.doi.org/10.13039/501100003745, Stiftelserna Wilhelm och Martina Lundgrens;
                Funded by: FundRef http://dx.doi.org/10.13039/501100004359, Vetenskapsrådet;
                Funded by: University of Gothenburg
                Categories
                Research
                Custom metadata
                © The Author(s) 2023

                idh-mutant gliomas,dna methylation profiling,tumor recurrence,longitudinal analysis

                Comments

                Comment on this article